Bristol Myers' Opdivo/Chemo Shows Durable Results At Four Years In Lung Cancer Patients

Bristol Myers Squibb & Co BMY released four-year follow-up data from the Phase 3 CheckMate -9LA trial to be presented in a late-breaking poster presentation at the 2023 American Society of Clinical Oncology (ASCO) annual meeting.
Also Read: Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients.
The results demonstrate that patients with metastatic non-small cell lung cancer (NSCLC) who received the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy had sustained, durable survival benefits compared to four cycles of chemotherapy alone at four years, with 21% of patients receiving the dual immunotherapy-based combination alive vs. 16% of those treated with chemotherapy alone.
Among patients with tumor PD-L1 expression <1%, the Overall Survival rate was 23% for those treated with the dual immunotherapy-based combination vs. 13% for chemotherapy alone, representing a 34% reduction in the risk of death.
No new safety signals were observed with Opdivo plus Yervoy with two cycles of chemotherapy with extended follow-up in the CheckMate -9LA trial.
Opdivo plus Yervoy-based combinations have shown significant improvements in OS in six Phase 3 clinical trials in five tumors to date.
Price Action: BMY shares are up 0.18% at $65.78 during the premarket session on the last check Monday.